Regulon

Regulon: R-2735

Regulons are regulatory units consisting of a coherently expressed set of genes and the associated regulator(s) whose binding site(s) they share.

Regulon Summary

Regulon summary table displays all associated information related to the specific regulon including the number of genes in the regulon, Hazard ratio, its Regulator, the Transcriptional Program that includes the regulon, Drugs that are associated with members of the regulon, together with mechanism of action and class, and enriched hallmarks of cancer if any.

GenesCox Hazard RatioRegulatorsCausal FlowsTranscriptional ProgramsHallmarks
50.46021510Pr-24Self sufficiency in growth signalInsensitivity to antigrowth signalEvading apoptosisSustained angiogenesisTissue invasion and metastasisTumor-promoting inflammationReprogramming energy metabolismEvading immune detectionLimitless replicative potentialGenome instability and mutation

Regulon Genes

List of genes that are included in the regulon. These genes have similar expression profiles in subset of patients and they share common binding motif for the Regulator of the regulon. Clicking on the gene name will take you to the gene specific page with more details. Please wait while information is collated from several resources after you click.

Entrez IDEnsEMBL IDPreferred NameUniprot ID
351 ENSG00000142192 APP P05067
7357 ENSG00000148154 UGCG Q16739
84159 ENSG00000150347 ARID5B Q14865
9334 ENSG00000158470 B4GALT5 O43286
7328 ENSG00000186591 UBE2H A4D1L5

Regulon Drugs

NameApproved SymbolTypeAction TypeMechanism of ActionMax Trial PhaseMax GBM Phase
PONEZUMABAPPAntibodyBINDING AGENTBeta amyloid A4 protein binding agent20
CRENEZUMABAPPAntibodyINHIBITORBeta amyloid A4 protein inhibitor30
ELIGLUSTATUGCGSmall moleculeINHIBITORCeramide glucosyltransferase inhibitor40
GANTENERUMABAPPAntibodyBINDING AGENTBeta amyloid A4 protein binding agent30
SOLANEZUMABAPPAntibodyBINDING AGENTBeta amyloid A4 protein binding agent30
ELIGLUSTAT TARTRATEUGCGSmall moleculeINHIBITORCeramide glucosyltransferase inhibitor40
MIGLUSTATUGCGSmall moleculeINHIBITORCeramide glucosyltransferase inhibitor40
BAPINEUZUMABAPPAntibodyBINDING AGENTBeta amyloid A4 protein binding agent30
GSK933776APPAntibodyBINDING AGENTBeta amyloid A4 protein binding agent20
LUCERASTATUGCGSmall moleculeINHIBITORCeramide glucosyltransferase inhibitor30
ADUCANUMABAPPAntibodyBINDING AGENTBeta amyloid A4 protein binding agent40
TRAMIPROSATEAPPSmall moleculeSTABILISERBeta amyloid A4 protein stabiliser30
LECANEMABAPPAntibodyINHIBITORBeta amyloid A4 protein inhibitor30
DONANEMABAPPAntibodyDISRUPTING AGENTBeta amyloid A4 protein disrupting agent30
VANUTIDE CRIDIFICARAPPProteinVACCINE ANTIGENBeta amyloid A4 protein vaccine antigen20

Causal Flows

Causal Flows are statistically significant links between putative causal events (somatic mutations, copy number variations, chromosomal translocations, etc.) and the activity levels of regulators and regulons. In the causal flow a mutation may causally activates or deactivates a downstream regulator which then might up- or down-regulates a regulon that contains genes with similar expression profiles and binding sites.

Causal Mechanistic Flows for Regulon R-2735

IDMutationRoleRegulatorRoleRegulon# downstream regulons# diffexp regulonsDrugs